Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Enikeev, S. Enikeeva, N.R. Bikmetova (Ufa, Russian Federation). PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage. Eur Respir J 2014; 44: Suppl. 58, 1514

Member's Comments

No comment yet.

Related content which might interest you: Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Effects of pulmonary rehabilitation on exacerbation number and severity in people with chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Survivin in patients with chronic obstructive pulmonary disease Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities) Source: International Congress 2014 – Comorbidities Year: 2014 Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 903-908 Year: 2001 Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Current maintenance treatment of chronic obstructive pulmonary disease in China Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Effectiveness of indacaterol with or without tiotropium in patients with moderate or severe chronic obstructive pulmonary disease (COPD) - the GOLDEN II study Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care Year: 2014 Dynamics of sputum antimicrobial peptide levels in chronic obstructive pulmonary disease (COPD) Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 Oscillating positive expiratory pressure (oPEP) therapy in chronic obstructive pulmonary disease and bronchiectasis Source: International Congress 2014 – Best posters in chronic care Year: 2014 Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006